Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multinational randomized double-blind placebo-controlled dose-ranging study of Lu AA21004 in major depressive disorder
jRCT2080221307Phase 3
- Sponsor
- Takeda
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (4 arms), sponsored by Takeda. Primary endpoints: Efficacy in major depressive disorder and Safety and tolerability of Lu AA21004.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080221307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221307.